Combination treatment with first-line lenvatinib plus pembrolizumab continued to show a clinically meaningful benefit at 2 years compared with sunitinib in patients with advanced renal cell carcinoma (RCC). These updated results of the CLEAR study were presented by Camillo G. Porta, of University of Bari, Italy, at the ESMO Congress 2022. ...
Renal Cell Carcinoma
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
The first PET scans using Illuccix, Telix’s PSMA-PET imaging agent, have been carried out in cooperation with BAMF Health.
Nanobubbles can target membrane proteins, including PSMA, to bind to receptors that are overexpressed in cancer cells.
Few biomarkers predict therapeutic response to radiation or adjunctive treatments in PCa patients treated with radiotherapy.